Magnesium in Gastrointestinal Disease
Observational · No treatment assigned · 1 site · University of Aarhus
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Colitis Ulcerosa, Colitis Ulcerative and Crohns Disease. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- \- Age 18 or older, mentally competent, and able to understand Danish.
- Group 1:
- \- Diagnosed with IBD (DK50X, Crohn's disease, or DK51X, ulcerative colitis), ileostomy (DZ932) or bile acid diarrhoea (DSK908B) (Se-HCAT scintigraphy showing residual activity <10%).
Plus 2 more requirement(s). There are also 2 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 120 participants are expected to take part.
- Start date: 2025-11-03.
- Main results expected around 2026-12-01 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Denmark.
Main thing being measured
- Percentage of participants with magnesium deficiency (magnesium retention >20%) (Immediately after completion of the magnesium infusion (Visit 3; urine collection completed within ~24 hours…)
In the researchers’ words
Individuals with gastrointestinal diseases - such as Crohn's disease, ulcerative colitis, ileostomy, or bile acid diarrhoea - are at increased risk of magnesium deficiency. Magnesium is a vital mineral that supports many essential functions in the body, including muscle contraction, nerve signalling, heart rhythm, and bone health.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Colitis Ulcerosa; Colitis Ulcerative; Crohns Disease; Morbus Crohn; Ileostomy - Stoma; Ileostoma; Ileostomies; Bile Acid Diarrhea; Bile Acid Malabsorption; Magnesium Deficiency; Magnesium Level; Magnesium |
| Lead sponsor | University of Aarhus |
| Collaborators | Aarhus University Hospital |
| Enrollment | 120 (estimated) |
| Start date | 2025-11-03 |
| Primary completion (est.) | 2026-12-01 |
| First posted | 2026-01-14 |
| Last updated | 2026-01-14 |
| Official title | Magnesium Status in Patients With Gastrointestinal Disease |
| ClinicalTrials.gov ID | NCT07338565 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: \- Age 18 or older, mentally competent, and able to understand Danish. Group 1: \- Diagnosed with IBD (DK50X, Crohn's disease, or DK51X, ulcerative colitis), ileostomy (DZ932) or bile acid diarrhoea (DSK908B) (Se-HCAT scintigraphy showing residual activity <10%). Group 2: \- Healthy individuals. Exclusion Criteria: * Pregnant or breastfeeding. * Use of oral magnesium supplements for more than 2 weeks before inclusion.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Hepatology and Gastroenterology, Aarhus University Hospital | Aarhus N | Denmark | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.